Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to explore the activity of chlorambucil, an alkylating
agent commonly used in chronic lymphocytic leukemia treatment, in metastatic patients, gBRCA,
including VUS, or DDR mutated, previously treated with a platinum-containing chemotherapy.